SEDANA MEDICAL Aktie

 

Enrolment of both US clinical trials completed, on track for first results in 2H. Second quarter 2024 · Net sales for the quarter totaled MSEK 41.1 (37.3), equivalent to an increase of 10% compared to the same quarter 2023. At constant exchange rates, sales increased by 10%. · Gross profit was MSEK 29.0 (26.6) equivalent to a margin of 71% (71%). · Earnings before interest, taxes, depreciation and amortization (EBITDA) totaled MSEK -13.9 (-10.7), equivalent to an EBITDA margin of -34% (-29%). EBITDA ex-US for the quarter was MSEK -10.8 (-10.2) corresponding to a margin of -26% (-...

Sedana Medical AB (publ) announces it has today entered into an agreement to acquire Innovatif Cekal, the supplier of the company's main product (Sedaconda ACD). The acquisition will enable better control of the supply chain and improved profitability by reducing the cost of goods sold. The purchase price of 34 MSEK on a cash and debt free basis will be financed with existing cash. “I am excited about acquiring Innovatif Cekal as this transaction is a perfect fit with our strategy. After streamlining our non-customer-facing functions and implementing a vigorous shift of resources towards the...

Sedana Medical AB (publ) plans to present its interim report for the second quarter of 2024 on Tuesday July 23 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the second quarter 2024 on Tuesday July 23 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Johan Spetz, CFO, and Peter Sackey, CMO, as well as answer questions.   Date: Tuesday, July 23, 2024 Time (CET): 13:30   More info and link...

Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025. “The completion of INSPiRE-ICU 2 concludes Sedana Medical´s clinical trials in the United States. Running this study together with esteemed...

Sedana Medical AB (publ)'s annual general meeting was held on Wednesday, 22 May 2024 and the main resolutions passed were the following. Regarding full details of the resolutions, referral is made to the notice convening the general meeting and the complete proposals. The notice convening the general meeting and the complete proposals are available at the company's website, www.sedanamedical.com.   Adoption of the income statements and the balance sheets The general meeting resolved to adopt the income statement and balance sheet and the consolidated income statement and...